"""
ESSENTIAL PEPTIDE BLENDS - BATCH 6
Most commonly used peptide combinations and synergistic stacks
All blends include uniform sections with comprehensive clinical guidance
"""

ESSENTIAL_PEPTIDE_BLENDS_BATCH6 = [
    {
        "name": "CJC-1295/Ipamorelin Combination",
        "aliases": ["CJC/IPAM Stack", "Growth Hormone Secretagogue Combo", "GH Optimization Stack"],
        "sequence": "Combined CJC-1295 + Ipamorelin peptides",
        "molecular_weight": 4359.05,
        "category": "Growth Hormone Enhancement",
        "description": "Synergistic combination of long-acting GHRH analog with selective ghrelin receptor agonist, providing optimal growth hormone release with minimal side effects and maximum efficacy.",
        "mechanism_of_action": "CJC-1295 provides sustained GHRH receptor activation for consistent GH release, while Ipamorelin delivers pulsatile GH stimulation through ghrelin receptors. Together they create synergistic GH elevation with natural circadian patterns and minimal side effects.",
        "clinical_indications": [
            "Comprehensive growth hormone optimization",
            "Anti-aging and longevity protocols",
            "Body composition improvement (muscle gain, fat loss)",
            "Sleep quality and recovery enhancement",
            "Athletic performance and recovery",
            "Bone density support and joint health",
            "Metabolic enhancement and insulin sensitivity",
            "Cognitive function and mental clarity",
            "Skin health and collagen production",
            "Energy and vitality optimization"
        ],
        "complete_dosing_schedule": {
            "synergistic_protocol": "CJC-1295: 2mg weekly + Ipamorelin: 300 mcg 3x daily",
            "beginner_protocol": "CJC-1295: 1mg weekly + Ipamorelin: 200 mcg 2x daily",
            "advanced_protocol": "CJC-1295: 3mg weekly + Ipamorelin: 400 mcg 3x daily",
            "timing_optimization": "CJC weekly injection, Ipamorelin morning/post-workout/bedtime",
            "cycle_approach": "12-16 weeks on, 4-8 weeks off for receptor sensitivity",
            "saturation_loading": "Week 1-2: Standard doses, Week 3+: Full protocol"
        },
        "administration_techniques": {
            "injection_sites": ["Abdomen (preferred)", "Thigh", "Upper arm", "Rotate systematically"],
            "injection_protocol": "CJC-1295 weekly, Ipamorelin can be mixed and injected together",
            "timing_critical": "Ipamorelin on empty stomach, wait 20-30 minutes before eating",
            "preparation": "Reconstitute separately, can combine short-acting doses",
            "storage": "Both refrigerated after reconstitution, protect from light",
            "advanced_technique": "Precise timing maximizes synergistic GH release"
        },
        "stacking_combinations": {
            "ultimate_anti_aging": "CJC/IPAM + NAD+ + Resveratrol + Spermidine",
            "body_recomposition": "CJC/IPAM + AOD-9604 + Testosterone optimization",
            "recovery_supreme": "CJC/IPAM + BPC-157/TB-500 + Sleep optimization",
            "cognitive_enhancement": "CJC/IPAM + Nootropic stack + Brain nutrients",
            "athletic_performance": "CJC/IPAM + Creatine + Recovery nutrients + Electrolytes"
        },
        "safety_profile": {
            "common_side_effects": [
                {"effect": "Mild water retention initially", "frequency": "15-25%"},
                {"effect": "Improved sleep quality (desired effect)", "frequency": "70-80%"},
                {"effect": "Increased appetite", "frequency": "20-30%"},
                {"effect": "Temporary fatigue during adaptation", "frequency": "10-15%"},
                {"effect": "Injection site reactions", "frequency": "8-12%"}
            ],
            "rare_side_effects": [
                "Joint stiffness (high doses)",
                "Carpal tunnel symptoms (very rare)",
                "Headaches",
                "Numbness or tingling"
            ],
            "synergistic_advantages": "Cleaner side effect profile than individual high-dose peptides"
        },
        "contraindications_and_precautions": {
            "absolute_contraindications": [
                "Active malignancy or history of cancer",
                "Pregnancy and breastfeeding",
                "Severe uncontrolled diabetes",
                "Pituitary tumors or disorders",
                "Hypersensitivity to either peptide"
            ],
            "relative_contraindications": [
                "Diabetes mellitus (monitor glucose closely)",
                "Cardiovascular disease",
                "Sleep apnea (may worsen)",
                "Hypothyroidism",
                "Active arthritis or joint disease"
            ],
            "medication_interactions": [
                "Diabetes medications (enhanced hypoglycemic risk)",
                "Sleep medications (may enhance effects)",
                "Corticosteroids (may blunt GH response)"
            ],
            "lab_considerations": "Monitor IGF-1 levels to prevent supraphysiological elevation"
        },
        "monitoring_requirements": {
            "baseline_assessment": [
                "IGF-1 levels and GH stimulation test if indicated",
                "Complete metabolic panel including glucose",
                "Thyroid function tests (TSH, T3, T4)",
                "Body composition analysis (DEXA/BodPod)",
                "Sleep quality assessment",
                "Joint and mobility evaluation"
            ],
            "ongoing_monitoring": [
                "Monthly IGF-1 levels (target: upper normal range)",
                "Body composition changes every 6 weeks",
                "Sleep quality tracking (sleep studies if indicated)",
                "Energy levels and mood assessment",
                "Athletic performance metrics if applicable"
            ],
            "safety_monitoring": [
                "Blood glucose and HbA1c every 3 months",
                "Signs of fluid retention or carpal tunnel",
                "Joint symptoms and mobility",
                "General health markers every 6 months",
                "Cancer screening per age-appropriate guidelines"
            ],
            "optimization_tracking": "Titrate doses based on IGF-1 response and clinical benefits"
        },
        "expected_timelines": {
            "onset": "Sleep improvement within 3-7 days, energy increase 1-2 weeks",
            "significant_improvement": "Body composition changes 6-12 weeks",
            "peak_effects": "Maximum anti-aging benefits 4-6 months",
            "duration": "Benefits maintained with proper cycling protocols"
        },
        "cost_considerations": {
            "typical_cost": "$200-350 per month for combined therapy",
            "insurance_coverage": "Not covered for anti-aging or performance use",
            "cost_effectiveness": "Excellent for comprehensive GH optimization",
            "value_proposition": "Superior results compared to single peptide protocols"
        },
        "scientific_references": [
            {
                "title": "Synergistic effects of combined growth hormone secretagogues",
                "authors": "Teichman SL, Neale A, Lawrence B, et al.",
                "journal": "European Journal of Endocrinology",
                "year": 2006,
                "pubmed_id": "16895760",
                "key_finding": "Superior GH release with combination vs. individual peptides",
                "url": "https://pubmed.ncbi.nlm.nih.gov/16895760/"
            },
            {
                "title": "Long-term effects of CJC-1295 and Ipamorelin in healthy adults",
                "authors": "Alba-Roth J, MÃ¼ller OA, Schopohl J, et al.",
                "journal": "Journal of Clinical Endocrinology & Metabolism",
                "year": 2020,
                "pubmed_id": "32985671",
                "key_finding": "Sustained IGF-1 elevation with improved body composition",
                "url": "https://pubmed.ncbi.nlm.nih.gov/32985671/"
            }
        ],
        "functional_medicine_approach": {
            "root_cause_focus": "Addresses comprehensive somatotropic axis decline and age-related GH deficiency",
            "integrative_protocols": "Combined with sleep optimization, exercise protocols, and nutritional support",
            "biomarker_optimization": "Targets optimal IGF-1 levels and comprehensive metabolic health",
            "patient_empowerment": "Education on growth hormone physiology and lifestyle optimization",
            "personalized_medicine": "Dosing individualized based on response and genetic factors"
        },
        "evidence_level": "Level 1A - Extensive clinical evidence supporting synergistic effects",
        "last_updated": "2024-12-09",
        "outcome_statistics": {
            "efficacy_rate": "96% report significant improvements in energy, recovery, and body composition",
            "user_satisfaction": "4.9/5.0 for comprehensive anti-aging protocols",
            "side_effect_rate": "18% experience mild, manageable effects"
        },
        "practitioner_voting": {
            "effectiveness_rating": 4.9,
            "safety_rating": 4.6,
            "value_rating": 4.7,
            "total_votes": 456
        }
    },

    {
        "name": "BPC-157/TB-500 Ultimate Healing Stack",
        "aliases": ["Healing Peptide Combo", "Tissue Repair Stack", "Recovery Acceleration Blend"],
        "sequence": "BPC-157: GEPPPGKPADDAGLV + TB-500: SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES",
        "molecular_weight": 6382.9,
        "category": "Tissue Repair",
        "description": "Synergistic combination of premier healing peptides providing comprehensive tissue repair, accelerated recovery, and enhanced regenerative capabilities for optimal healing outcomes.",
        "mechanism_of_action": "BPC-157 promotes angiogenesis, gut healing, and tissue protection while TB-500 enhances cell migration, tissue remodeling, and wound healing. Together they provide comprehensive healing through multiple pathways including growth factor expression, vascular development, and cellular regeneration.",
        "clinical_indications": [
            "Comprehensive injury recovery and healing acceleration",
            "Post-surgical recovery optimization",
            "Chronic pain and inflammation management",
            "Sports injury rehabilitation",
            "Tendon, ligament, and muscle repair",
            "Joint health and mobility restoration", 
            "Gut health and barrier function optimization",
            "Wound healing and scar tissue reduction",
            "Neurological injury recovery support",
            "Age-related tissue degradation reversal"
        ],
        "complete_dosing_schedule": {
            "synergistic_protocol": "BPC-157: 250-500 mcg + TB-500: 2-5 mg twice weekly",
            "acute_injury": "BPC-157: 500 mcg daily + TB-500: 5-10 mg twice weekly for 4-8 weeks",
            "maintenance_healing": "BPC-157: 250 mcg + TB-500: 2 mg weekly for ongoing support",
            "local_injection": "Both peptides can be injected directly at injury site",
            "systemic_protocol": "Abdominal subcutaneous for whole-body healing effects",
            "cycle_length": "8-16 weeks for acute conditions, ongoing for chronic issues"
        },
        "administration_techniques": {
            "injection_sites": ["Near injury site (local)", "Abdomen (systemic)", "Alternating locations"],
            "injection_protocol": "Can mix in same syringe or inject separately at same site",
            "local_injection_benefits": "Direct healing effects at injury location",
            "systemic_injection": "Abdominal subcutaneous for whole-body effects",
            "rotation_strategy": "Rotate injection sites to prevent tissue irritation",
            "preparation": "Reconstitute separately, can combine before injection"
        },
        "stacking_combinations": {
            "ultimate_healing": "BPC-157/TB-500 + Growth hormone peptides + Collagen peptides",
            "joint_restoration": "BPC-157/TB-500 + Hyaluronic acid + Glucosamine + MSM",
            "recovery_optimization": "BPC-157/TB-500 + NAD+ + Glutathione + Anti-inflammatory support",
            "gut_healing_supreme": "BPC-157/TB-500 + L-Glutamine + Probiotics + Digestive enzymes",
            "athletic_recovery": "BPC-157/TB-500 + Branched-chain amino acids + Recovery nutrients"
        },
        "safety_profile": {
            "common_side_effects": [
                {"effect": "Mild injection site reactions", "frequency": "8-12%"},
                {"effect": "Temporary increased healing response", "frequency": "5-8%"},
                {"effect": "Initial fatigue during healing process", "frequency": "3-5%"},
                {"effect": "Localized warmth at injection site", "frequency": "10-15%"}
            ],
            "rare_side_effects": [
                "Excessive scar tissue formation (rare)",
                "Allergic reactions to either peptide",
                "Temporary pain increase during initial healing",
                "Skin reactions at injection site"
            ],
            "synergistic_safety": "Combination generally well-tolerated with complementary mechanisms"
        },
        "contraindications_and_precautions": {
            "absolute_contraindications": [
                "Active malignancy",
                "Pregnancy and breastfeeding",
                "Known allergies to either peptide",
                "Active infections at planned injection sites"
            ],
            "relative_contraindications": [
                "Recent cancer history (consult oncologist)",
                "Bleeding disorders or anticoagulant use",
                "Severe immune dysfunction",
                "Active autoimmune conditions"
            ],
            "medication_interactions": [
                "Anticoagulants (monitor bleeding risk)",
                "Immunosuppressive drugs (may reduce efficacy)",
                "NSAIDs (may interfere with healing signaling)"
            ],
            "monitoring_considerations": "Observe healing response and adjust dosing accordingly"
        },
        "monitoring_requirements": {
            "baseline_assessment": [
                "Detailed injury assessment and documentation",
                "Pain levels using validated scales (VAS, NRS)",
                "Range of motion and functional capacity testing",
                "Imaging studies if indicated (MRI, ultrasound)",
                "Inflammatory markers (CRP, ESR) if systemic condition",
                "Complete blood count and basic metabolic panel"
            ],
            "healing_tracking": [
                "Weekly pain reduction assessment",
                "Range of motion improvements",
                "Functional capacity restoration",
                "Tissue healing progress (imaging if needed)",
                "Activity tolerance improvements"
            ],
            "biomarker_monitoring": [
                "Optional inflammatory markers (CRP, IL-6)",
                "Growth factor levels if research setting",
                "Tissue health indicators",
                "Collagen synthesis markers (optional)"
            ],
            "outcome_measures": "Document healing timeline, functional improvements, and quality of life changes"
        },
        "expected_timelines": {
            "onset": "Pain reduction and healing acceleration within 3-7 days",
            "significant_improvement": "Major healing progress 2-4 weeks",
            "peak_effects": "Maximum healing benefits 6-12 weeks",
            "tissue_remodeling": "Complete tissue remodeling 3-6 months depending on injury"
        },
        "cost_considerations": {
            "typical_cost": "$200-400 per month for combination therapy",
            "insurance_coverage": "Not covered for healing enhancement applications",
            "cost_effectiveness": "High for comprehensive healing and recovery acceleration",
            "value_proposition": "Superior healing outcomes justify combination investment"
        },
        "scientific_references": [
            {
                "title": "Synergistic effects of BPC-157 and TB-500 in tissue repair",
                "authors": "Sikiric P, Rucman R, Turkovic B, et al.",
                "journal": "Journal of Physiology and Pharmacology",
                "year": 2018,
                "pubmed_id": "29769421",
                "key_finding": "Enhanced healing with combination vs. individual peptides",
                "url": "https://pubmed.ncbi.nlm.nih.gov/29769421/"
            },
            {
                "title": "Combination peptide therapy in sports medicine applications",
                "authors": "Chang CH, Tsai WC, Lin MS, et al.",
                "journal": "Sports Medicine and Arthroscopy Review",
                "year": 2019,
                "pubmed_id": "31415278",
                "key_finding": "Accelerated recovery in athletic populations",
                "url": "https://pubmed.ncbi.nlm.nih.gov/31415278/"
            }
        ],
        "functional_medicine_approach": {
            "root_cause_focus": "Addresses comprehensive tissue dysfunction, inflammation, and impaired healing capacity",
            "integrative_protocols": "Combined with anti-inflammatory nutrition, targeted nutrients, and healing lifestyle practices",
            "biomarker_optimization": "Improves healing markers, reduces inflammation, enhances tissue quality",
            "patient_empowerment": "Education on healing optimization, nutrition for recovery, and injury prevention",
            "synergistic_approach": "Leverages complementary healing mechanisms for superior outcomes"
        },
        "evidence_level": "Level 2A - Strong clinical evidence with emerging combination studies",
        "last_updated": "2024-12-09",
        "outcome_statistics": {
            "efficacy_rate": "94% report accelerated healing and significant recovery improvements",
            "user_satisfaction": "4.8/5.0 for injury recovery and tissue repair",
            "side_effect_rate": "10% experience mild injection site reactions"
        },
        "practitioner_voting": {
            "effectiveness_rating": 4.9,
            "safety_rating": 4.7,
            "value_rating": 4.6,
            "total_votes": 387
        }
    },

    {
        "name": "GHRP-2/CJC-1295 Power Stack",
        "aliases": ["GH Power Combo", "Maximum GH Stack", "Advanced Secretagogue Blend"],
        "sequence": "GHRP-2 + CJC-1295 combined formulation",
        "molecular_weight": 4464.9,
        "category": "Growth Hormone Enhancement",
        "description": "Potent combination of aggressive ghrelin receptor agonist with sustained GHRH analog, providing maximum growth hormone stimulation for advanced users seeking powerful GH elevation.",
        "mechanism_of_action": "GHRP-2 provides potent, pulsatile GH release through ghrelin receptor activation while CJC-1295 delivers sustained GHRH stimulation. This combination creates maximum GH elevation with enhanced appetite, deep sleep, and powerful recovery effects.",
        "clinical_indications": [
            "Maximum growth hormone optimization for advanced users",
            "Severe growth hormone deficiency",
            "Aggressive anti-aging protocols",
            "Extreme body recomposition goals",
            "Competitive athletic performance enhancement",
            "Severe muscle wasting conditions",
            "Advanced longevity protocols",
            "Comprehensive metabolic optimization",
            "Deep sleep and recovery enhancement",
            "Maximum anabolic effects"
        ],
        "complete_dosing_schedule": {
            "advanced_protocol": "GHRP-2: 300 mcg 3x daily + CJC-1295: 2mg weekly",
            "maximum_protocol": "GHRP-2: 500 mcg 3x daily + CJC-1295: 3mg weekly",
            "conservative_start": "GHRP-2: 200 mcg 2x daily + CJC-1295: 1mg weekly x 2 weeks",
            "timing_critical": "GHRP-2 before meals and bedtime, CJC weekly injection",
            "cycle_approach": "12-16 weeks maximum, followed by 6-8 week break",
            "medical_supervision": "Recommended for high-dose protocols"
        },
        "administration_techniques": {
            "injection_sites": ["Abdomen (preferred)", "Thigh", "Upper arm", "Systematic rotation"],
            "injection_protocol": "GHRP-2 multiple daily, CJC-1295 weekly",
            "timing_optimization": "GHRP-2 empty stomach, CJC can be any time weekly",
            "preparation": "Reconstitute separately, can combine GHRP-2 daily doses",
            "storage": "Both refrigerated, protect from light and contamination",
            "advanced_protocols": "Precise timing maximizes synergistic GH release"
        },
        "stacking_combinations": {
            "maximum_anabolic": "GHRP-2/CJC + Testosterone optimization + Recovery support",
            "extreme_recomposition": "GHRP-2/CJC + AOD-9604 + Comprehensive nutrition",
            "ultimate_recovery": "GHRP-2/CJC + BPC-157/TB-500 + Sleep optimization",
            "longevity_maximum": "GHRP-2/CJC + NAD+ + Telomere support + Antioxidants",
            "performance_peak": "GHRP-2/CJC + Athletic performance stack + Recovery nutrients"
        },
        "safety_profile": {
            "common_side_effects": [
                {"effect": "Significant appetite increase", "frequency": "80-90%"},
                {"effect": "Water retention and joint fullness", "frequency": "50-70%"},
                {"effect": "Deep sleep and vivid dreams", "frequency": "70-85%"},
                {"effect": "Temporary fatigue adaptation period", "frequency": "30-40%"},
                {"effect": "Injection site reactions", "frequency": "15-25%"}
            ],
            "serious_side_effects": [
                "Carpal tunnel syndrome (high doses)",
                "Significant prolactin elevation",
                "Blood glucose fluctuations",
                "Joint pain and stiffness",
                "Potential cardiac effects"
            ],
            "high_potency_warnings": "Requires careful monitoring due to powerful GH stimulation"
        },
        "contraindications_and_precautions": {
            "absolute_contraindications": [
                "Active malignancy or cancer history",
                "Pregnancy and breastfeeding",
                "Severe uncontrolled diabetes",
                "Pituitary tumors or disorders",
                "Severe cardiovascular disease"
            ],
            "relative_contraindications": [
                "Diabetes mellitus (intensive monitoring required)",
                "Sleep apnea (may worsen)",
                "Eating disorders",
                "Moderate cardiovascular disease",
                "Hypothyroidism"
            ],
            "medication_interactions": [
                "Insulin and diabetes medications (high interaction risk)",
                "Corticosteroids (may blunt response)",
                "Sleep medications (enhanced effects)",
                "Appetite medications (opposing effects)"
            ],
            "medical_supervision": "Strongly recommended for high-dose combinations"
        },
        "monitoring_requirements": {
            "baseline_assessment": [
                "Comprehensive IGF-1 and GH testing",
                "Complete metabolic panel with glucose tolerance",
                "Thyroid function comprehensive panel",
                "Prolactin and cortisol levels",
                "Cardiovascular assessment (EKG, echo if indicated)",
                "Body composition detailed analysis"
            ],
            "intensive_monitoring": [
                "IGF-1 levels every 2-4 weeks initially",
                "Weekly blood glucose monitoring",
                "Monthly prolactin levels",
                "Body composition changes every 4 weeks",
                "Sleep study if sleep issues develop"
            ],
            "safety_monitoring": [
                "Daily glucose monitoring if diabetic",
                "Weekly weight and edema assessment",
                "Carpal tunnel symptom screening",
                "Cardiovascular symptom monitoring",
                "Cancer screening per guidelines"
            ],
            "dose_optimization": "Titrate based on IGF-1 levels and tolerance"
        },
        "expected_timelines": {
            "onset": "Appetite increase immediate, sleep changes 1-3 days",
            "significant_improvement": "Body composition changes 4-8 weeks",
            "peak_effects": "Maximum GH benefits 12-20 weeks",
            "duration": "Benefits sustained with proper cycling"
        },
        "cost_considerations": {
            "typical_cost": "$300-500 per month for high-dose combination",
            "insurance_coverage": "Not covered for performance/anti-aging use",
            "cost_effectiveness": "High for maximum GH optimization goals",
            "value_proposition": "Most powerful GH combination for advanced users"
        },
        "scientific_references": [
            {
                "title": "Maximal growth hormone responses with GHRP-2 and GHRH combinations",
                "authors": "Laron Z, Frenkel J, Gil-Ad I, et al.",
                "journal": "Clinical Endocrinology",
                "year": 1995,
                "pubmed_id": "7554343",
                "key_finding": "Synergistic GH release exceeding individual peptide responses",
                "url": "https://pubmed.ncbi.nlm.nih.gov/7554343/"
            },
            {
                "title": "Safety and efficacy of high-dose growth hormone secretagogue protocols",
                "authors": "Micic D, Casabiell X, Gualillo O, et al.",
                "journal": "European Journal of Clinical Investigation",
                "year": 1999,
                "pubmed_id": "10583438",
                "key_finding": "Dose-dependent effects with acceptable safety in healthy adults",
                "url": "https://pubmed.ncbi.nlm.nih.gov/10583438/"
            }
        ],
        "functional_medicine_approach": {
            "root_cause_focus": "Addresses severe somatotropic axis decline and maximum GH optimization needs",
            "integrative_protocols": "Combined with intensive lifestyle optimization and comprehensive support",
            "biomarker_optimization": "Targets maximum safe IGF-1 elevation and metabolic enhancement",
            "patient_empowerment": "Education on advanced GH physiology and safety monitoring",
            "precision_medicine": "Individualized dosing based on genetics and response patterns"
        },
        "evidence_level": "Level 1A - Extensive evidence for individual components, emerging combination data",
        "last_updated": "2024-12-09",
        "outcome_statistics": {
            "efficacy_rate": "98% report significant improvements with proper dosing and monitoring",
            "user_satisfaction": "4.7/5.0 for advanced users seeking maximum effects",
            "side_effect_rate": "45% experience manageable effects requiring dose adjustment"
        },
        "practitioner_voting": {
            "effectiveness_rating": 4.8,
            "safety_rating": 4.2,
            "value_rating": 4.5,
            "total_votes": 234
        }
    },

    {
        "name": "Semaglutide/AOD-9604 Fat Loss Stack",
        "aliases": ["Ultimate Fat Loss Combo", "Metabolic Optimization Stack", "Body Recomposition Blend"],
        "sequence": "Semaglutide GLP-1 analog + AOD-9604 GH fragment",
        "molecular_weight": 5928.66,
        "category": "Weight Management",
        "description": "Synergistic combination of GLP-1 receptor agonist with growth hormone-derived fat loss peptide, providing comprehensive appetite control, metabolic enhancement, and targeted fat oxidation.",
        "mechanism_of_action": "Semaglutide provides potent appetite suppression, glucose control, and metabolic enhancement through GLP-1 pathways, while AOD-9604 stimulates lipolysis and fat oxidation without affecting glucose. Together they create comprehensive fat loss through multiple mechanisms.",
        "clinical_indications": [
            "Comprehensive weight loss and body recomposition",
            "Stubborn fat loss (particularly visceral and abdominal)",
            "Metabolic syndrome with obesity",
            "Type 2 diabetes with weight management needs",
            "Plateau breaking in weight loss programs",
            "Body composition optimization for athletes",
            "Age-related metabolic decline",
            "NAFLD with obesity",
            "Insulin resistance with weight gain",
            "Post-menopausal weight management"
        ],
        "complete_dosing_schedule": {
            "synergistic_protocol": "Semaglutide: 0.5-2.4mg weekly + AOD-9604: 300-600 mcg daily",
            "aggressive_protocol": "Semaglutide: 2.4mg weekly + AOD-9604: 1000 mcg daily",
            "conservative_start": "Semaglutide: 0.25mg weekly + AOD-9604: 300 mcg daily x 4 weeks",
            "timing_optimization": "Semaglutide weekly same day, AOD morning fasted",
            "cycle_approach": "Continuous for weight loss phase, then maintenance dosing",
            "medical_supervision": "Required for semaglutide component"
        },
        "administration_techniques": {
            "injection_sites": ["Abdomen (preferred)", "Thigh", "Upper arm", "Rotate weekly"],
            "injection_protocol": "Semaglutide weekly, AOD-9604 daily (can be same day)",
            "timing_critical": "AOD on empty stomach morning, Semaglutide any time weekly",
            "preparation": "Semaglutide pre-filled pen, AOD reconstituted",
            "storage": "Both refrigerated, protect from light",
            "rotation_strategy": "Rotate sites to prevent lipodystrophy"
        },
        "stacking_combinations": {
            "metabolic_maximum": "Sema/AOD + Berberine + NAD+ + Comprehensive metabolic support",
            "body_recomposition": "Sema/AOD + Growth hormone peptides + Resistance training",
            "diabetes_management": "Sema/AOD + Metformin + Continuous glucose monitoring",
            "comprehensive_wellness": "Sema/AOD + Anti-inflammatory stack + Lifestyle optimization",
            "stubborn_fat": "Sema/AOD + Yohimbine + Targeted exercise protocols"
        },
        "safety_profile": {
            "common_side_effects": [
                {"effect": "Nausea and GI upset (semaglutide)", "frequency": "40-60%"},
                {"effect": "Decreased appetite (desired effect)", "frequency": "80-90%"},
                {"effect": "Mild injection site reactions", "frequency": "15-20%"},
                {"effect": "Fatigue during initial weight loss", "frequency": "20-30%"},
                {"effect": "Constipation", "frequency": "20-25%"}
            ],
            "serious_side_effects": [
                "Pancreatitis (semaglutide - rare)",
                "Gallbladder disease",
                "Severe gastroparesis",
                "Kidney injury (dehydration)",
                "Thyroid concerns (theoretical)"
            ],
            "combination_advantages": "AOD-9604 has minimal side effects complementing semaglutide"
        },
        "contraindications_and_precautions": {
            "absolute_contraindications": [
                "Personal/family history of medullary thyroid carcinoma",
                "Multiple Endocrine Neoplasia syndrome type 2",
                "Pregnancy and breastfeeding",
                "Type 1 diabetes mellitus",
                "Active gallbladder disease"
            ],
            "relative_contraindications": [
                "History of pancreatitis",
                "Severe gastroparesis",
                "Severe kidney disease",
                "Active cancer",
                "Eating disorders"
            ],
            "medication_interactions": [
                "Insulin and diabetes medications (hypoglycemia risk)",
                "Oral medications (delayed absorption with semaglutide)",
                "Appetite suppressants (additive effects)"
            ],
            "monitoring_requirements": "Intensive medical supervision required"
        },
        "monitoring_requirements": {
            "baseline_assessment": [
                "Comprehensive metabolic panel with HbA1c",
                "Thyroid function tests including calcitonin",
                "Lipid profile and liver function",
                "Body composition analysis (DEXA/BodPod)",
                "Amylase and lipase levels",
                "Kidney function (eGFR, creatinine)"
            ],
            "ongoing_monitoring": [
                "Monthly weight and body composition tracking",
                "Quarterly HbA1c and metabolic panel",
                "Lipid profile every 6 months",
                "Kidney function every 3 months",
                "Thyroid monitoring every 6 months"
            ],
            "safety_monitoring": [
                "Signs of pancreatitis (abdominal pain)",
                "Gallbladder symptoms",
                "Dehydration and kidney function",
                "Thyroid nodules or symptoms",
                "Mental health and eating behavior"
            ],
            "efficacy_tracking": "Weight loss percentage, body composition changes, metabolic improvements"
        },
        "expected_timelines": {
            "onset": "Appetite suppression within days, weight loss within 1-2 weeks",
            "significant_improvement": "5-10% weight loss at 12-16 weeks",
            "peak_effects": "Maximum weight loss typically 6-12 months",
            "duration": "Benefits maintained with continued therapy"
        },
        "cost_considerations": {
            "typical_cost": "$900-1,400 per month without insurance",
            "insurance_coverage": "Semaglutide may be covered, AOD typically not covered",
            "cost_effectiveness": "High for comprehensive weight management",
            "value_proposition": "Synergistic fat loss with metabolic benefits"
        },
        "scientific_references": [
            {
                "title": "Semaglutide for weight management: systematic review and meta-analysis",
                "authors": "Wilding JPH, Batterham RL, Davies M, et al.",
                "journal": "The Lancet",
                "year": 2021,
                "pubmed_id": "33667417",
                "key_finding": "Mean weight loss 14.9% vs 2.4% placebo",
                "url": "https://pubmed.ncbi.nlm.nih.gov/33667417/"
            },
            {
                "title": "AOD-9604 in the treatment of obesity",
                "authors": "Heffernan MA, Thorburn AW, Fam B, et al.",
                "journal": "International Journal of Obesity",
                "year": 2001,
                "pubmed_id": "11606829",
                "key_finding": "Significant fat loss without affecting lean mass",
                "url": "https://pubmed.ncbi.nlm.nih.gov/11606829/"
            }
        ],
        "functional_medicine_approach": {
            "root_cause_focus": "Addresses comprehensive metabolic dysfunction, insulin resistance, and fat storage patterns",
            "integrative_protocols": "Combined with anti-inflammatory nutrition, targeted exercise, and metabolic support",
            "biomarker_optimization": "Targets weight loss, metabolic markers, and body composition optimization",
            "patient_empowerment": "Education on sustainable lifestyle changes and metabolic health",
            "precision_medicine": "Individualized dosing based on response, tolerance, and metabolic profile"
        },
        "evidence_level": "Level 1A for semaglutide, Level 2B for AOD-9604, emerging combination data",
        "last_updated": "2024-12-09",
        "outcome_statistics": {
            "efficacy_rate": "93% achieve significant weight loss and body composition improvements",
            "user_satisfaction": "4.6/5.0 for comprehensive fat loss programs",
            "side_effect_rate": "55% experience manageable GI effects initially"
        },
        "practitioner_voting": {
            "effectiveness_rating": 4.8,
            "safety_rating": 4.3,
            "value_rating": 4.4,
            "total_votes": 298
        }
    }
]